Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3038508 Target Snapshot

Topoisomerase IV · PROTEIN COMPLEX · Staphylococcus aureus

Back to Search Search this target Browse approvals Evidence Card
286Compounds
61Assays
3Approved Drugs
251.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Topoisomerase IV shows approved-linked disease relevance led by impetigo. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P0C1U9. Start with impetigo, then reuse UniProt P0C1U9 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with impetigo, then reuse UniProt P0C1U9 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
impetigo

Topoisomerase IV shows approved-linked disease relevance led by impetigo. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with impetigo because it currently carries approved-linked support. Linked drugs include OZENOXACIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Topoisomerase IV as ChEMBL target CHEMBL3038508, mapped to UniProt P0C1U9. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Topoisomerase IV
PROTEIN COMPLEX · Staphylococcus aureus
As of 2026-09-14
ChEMBL target ID
CHEMBL3038508
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P0C1U9
DNA topoisomerase 4 subunit A
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Topoisomerase IV is the right protein anchor across sources, using UniProt P0C1U9 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why impetigo is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameTopoisomerase IV
Target TypePROTEIN COMPLEX
OrganismStaphylococcus aureus
UniProtP0C1U9
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDNA topoisomerase 4 subunit A
UniProt AccessionP0C1U9
Component TypeProtein
Sequence Length800 aa

DNA topoisomerase 4 subunit A

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Topoisomerase IV, mapped to UniProt P0C1U9. ChEMBL maps the protein component as DNA topoisomerase 4 subunit A. Sequence length is 800 aa.

Mapped IDP0C1U9
Review nameTopoisomerase IV
OrganismStaphylococcus aureus
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Topoisomerase IV shows approved-linked disease relevance led by impetigo. 4 more disease programs remain visible in the same review block.

Approved-linked Approved
impetigo
1 linked drug · 1 direct · 1 efficacy
Linked drugOZENOXACIN
Clinical signal Phase II
infectious otitis media
1 linked drug · 1 direct · 1 efficacy
Linked drugFINAFLOXACIN
Clinical signal Phase II
injury
1 linked drug · 1 direct · 1 efficacy
Linked drugOZENOXACIN
Clinical signal Phase II
Otitis media
1 linked drug · 1 direct · 1 efficacy
Linked drugFINAFLOXACIN
Clinical signal Phase II
urinary tract infection
1 linked drug · 1 direct · 1 efficacy
Linked drugFINAFLOXACIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with impetigo because it currently carries approved-linked support. Linked drugs include OZENOXACIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseimpetigo
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
1
Phase III
Assay Mix

Activity Type Distribution

IC50248.0
KI3.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5288212 8.1 IC50 8.0 Preclinical
CHEMBL2220900 7.92 Ki 12.0 Preclinical
CHEMBL4873479 7.3 IC50 50.0 Preclinical
CHEMBL5441103 7.08 IC50 84.0 Preclinical
CHEMBL4879265 7.05 IC50 90.0 Preclinical
CHEMBL2424893 6.9 IC50 125.0 Preclinical
CHEMBL5395597 6.75 IC50 177.0 Preclinical
CHEMBL4787821 6.72 IC50 190.0 Preclinical
CHEMBL4879088 6.67 IC50 215.0 Preclinical
CHEMBL5090088 6.64 IC50 230.0 Preclinical
Distribution

pChEMBL Value Distribution

54
5.0
44
5.5
32
6.0
13
6.5
4
7.0
1
7.5
1
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

CIPROFLOXACIN
CHEMBL8
Approved 1987
Properties Compare Identifier
Assay Landscape

Assay Landscape

61
Total Assays
169
Tested Compounds
1
Assay Types
Binding — 61 assays, 169 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 59 168 5.6
assay format 1 0 —
cell-based format 1 1 6.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine